{"id":"ciiit","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of diabetic ketoacidosis"},{"rate":"5-10%","effect":"Genital yeast infections"},{"rate":"null","effect":"Increased risk of amputations"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, CIIIT reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes. CIIIT's SGLT2 inhibition also has a secondary effect of reducing sodium reabsorption, which may contribute to its cardiovascular benefits.","oneSentence":"CIIIT is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:05:53.593Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"},{"name":"Cardiovascular risk reduction in patients with type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT00594152","phase":"PHASE3","title":"Anti-Nephropathic Effects of Chronic Intermittent Intravenous Insulin Therapy (CIIIT)","status":"COMPLETED","sponsor":"Joslin Diabetes Center","startDate":"1993-01","conditions":"Diabetic Nephropathy, Diabetic Retinopathy","enrollment":71}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CIIIT","genericName":"CIIIT","companyName":"Joslin Diabetes Center","companyId":"joslin-diabetes-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CIIIT is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes, Cardiovascular risk reduction in patients with type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}